






































The partial saphenous nerve injury model of pain
impairs reward-related learning but not reward
sensitivity or motivation
Caroline E. Phelpsa,b, Bridget M. Lumba, Lucy F. Donaldsonc, Emma S. Robinsona,*
Abstract
Chronic pain is highly comorbidwith affective disorders, includingmajor depressive disorder. A core feature ofmajor depressive disorder is
a loss of interest in previously rewarding activities. Major depressive disorder is also associated with negative affective biases where
cognitive processes are modulated by the affective state. Previous work from our laboratory has shown that reward-related learning and
memory is impaired in rodentmodels of depression generated through a variety of differentmanipulations. This study investigated different
aspects of reward-relatedbehaviour in a rodentmodel of chronic pain, thepartial saphenous nerve injury (PSNI). Usingour reward-learning
assay, an impairment in reward learning was observedwith no difference in sucrose preference, consistent with a lack of effect on reward
sensitivity and similar to the effects seen in depression models. In a successive negative contrast task, chronic pain was not associated
with changes inmotivation for reward either under normal conditions or when rewardwas devalued although both shamandPSNI groups
exhibited the expected negative contrast effect. In the affective bias test, PSNI rats developed a positive affective bias when treated with
gabapentin, an effect not seen in the controls suggesting an association with the antinociceptive effects of the drug inducing a relatively
more positive affective state. Together, these data suggest that there are changes in reward-related cognition in this chronic pain model
consistent with previous findings in rodentmodels of depression. The effects seenwith gabapentin suggest that pain-associated negative
affective state may be remediated by this atypical analgesic.
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1. Introduction
Chronic pain is highly comorbid with affective disorders
including major depressive disorder (MDD).3,33 Despite this,
it is not yet understood whether this comorbidity arises through
overlapping neurobiology63 or independent mechanisms.6
Understanding the mechanisms which contribute to complex
conditions such as MDD and/or chronic pain can be
challenging in patients. Rodent studies offer a route to better
understand these relationships, but methods available are
limited.48,49 Models of behavioural despair were developed to
predict antidepressant efficacy but are now often used to test
for depression-like phenotypes, despite recent concerns that
these tests relate more to stress coping than depression.9,57
Previous studies have reported depression-like phenotypes in
chronic pain models using the forced swim1,2,5 and tail
suspension21,40,62 tests. However, as well as potential issues
relating to what these assays measure, both tests may be
confounded by the locomotor or motivational differences in
pain models.38,49 An alternative approach is to measure
changes in sensitivity to reward using methods such as
sucrose preference tests (SPTs).34 In chronic pain models,
some laboratories report deficits2,12,16,35,54,60,62 whereas
others found no difference.17,46,47,58 Questions about whether
changes in reward sensitivity are a hallmark of MDD have also
arisen in a human version, the sweet taste test, which gives
mixed results in MDD.13 No effects in other tests such as
intracranial self-stimulation15 or facial reactions to a delivered
sucrose solution41 have been observed in pain models.
Reward processing is complex and involves both reward
sensitivity and motivation but is also influenced by prior
experiences and reward-related cognition for example, learn-
ing and memory, decision-making (for review see Refs. 44,48).
Little studied in the pain field is the role of neuropsychological
mechanisms in the development ofmood-related symptoms. The
potential contribution of neuropsychological mechanisms inMDD
was first proposed by Beck in the 1960s, and there has been
renewed interest in recent years.19,20,44,48 Affective state–
induced biases in cognition and executive function have been
observed in MDD patients and at-risk individuals in domains
including attention, learning and memory, decision-making, and
emotional interpretation.7,28,32 Studies in both patients and
healthy volunteers have also found that traditional monoaminer-
gic antidepressants can induce acute, positive biases in these
domains, effects that may contribute to their clinical efficacy.20,44
Recent translation of human neuropsychological methods for
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application in preclinical models have also found similar affective
biases in rodents.25,50,53
In this study, we used the previously characterised partial
saphenous nerve injury model (PSNI).27,59 We tested rats using
our reward learning assay (RLA) which we have previously found
reveals impairments in putative models of depression.51,53 We
compared effects with assays of reward sensitivity and
motivation, including using a successive negative contrast
task11,36 to look at reward motivation during devalue of reward.
We also used our affective bias test (ABT)50 to determine whether
acute antinociception would modify affective biases consistent
with an acute, treatment-induced change in the affective state
(see methods for additional detail).
2. Methods
2.1. Animals
Studies used 2 cohorts ofmale Lister-hooded rats (Harlan, United
Kingdom) (cohort 1 5 reward learning, ABT and SPT cohort 2 5
successive negative contrast (SNC) and von Frey, Figure 1). In
these initial proof of concept studies, only a single sex of animals
was used; however, understanding the impact of sex will be an
important follow-on study should the hypotheses being tested
here be substantiated. We have previously established that
affective biases in the ABT are present in both male and female
rats,25 but the lack of a sex-related comparisons is a limitation of
the study design. Each cohort of rats were run through the same
procedures for the RLA followed by the ABT, and, then, the
results for each experiment pooled to provide the final n number.
This was necessary as the bowl digging tasks are limited in terms
of the numbers of animals which can be run at the same time.
Rats for cohort 1were 280 to 320 g at the start of testing, whereas
rats for cohort 2 were 360 to 400 g. All rats were housed in same-
treatment pairs, in controlled humidity and temperature condi-
tions and under a 12-hour light-dark cycle (lights off at 0800).
Testing was performed during the dark phase of the cycle, under
red light, between 09:00 to 18:00.Water was provided ab libitum,
and food was restricted to approximately 20 g per day,
maintaining rats at ;95% of their free feeding weight matched
to their normal growth curve. All procedures were in accordance
with the United Kingdom Animals (Scientific Procedures) Act
1986 and EU2010/63/EU, local institutional guidelines and the
International Association for the Study of Pain. All studies were
reviewed by the local animal welfare and ethical review body.
Procedures are reported in accordance with the ARRIVE
guidelines.29
2.2. Partial saphenous nerve injury surgery
Rats had either sham or PSNI surgery (cohort 1: n 5 16/grp),
cohort 2: n 5 12/grp). We chose this model because it uses a
sensory nerve injury and lacks the overt effects on limb function
seen with sciatic nerve injury models. Surgeries were as
described previously.26,27,59 In brief, under anaesthesia (5%
induction, 2% maintenance isoflurane in O2), a ;1 cm incision
was made on the anterior surface of the right hind leg. The
saphenous nerve was blunt dissected from surrounding tissues.
Proximal to any nerve branches, the nerve sheath was split
longitudinally and the nerve gently blunt dissected longitudinally
along the midline into 2 sections. A 4-0 nonabsorbable nylon
sterile suture (Mersilk, Ethicon) was passed around only the lateral
section and tied tightly. The wounds were closed using either the
same suture externally (cohort 1) or intradermal absorbable
suture (4-0 Vicryl suture, Ethicon) (cohort 2). Intradermal absorb-
able sutures were used for the second cohort to improve wound
healing during recovery. Sham surgery was identical apart from
there was no ligation of the saphenous nerve. The timing of
surgery relative to behavioural training and testing in the different
assays is illustrated in Figure 1.
2.3. Measurement of mechanical nociceptive behaviour
Mechanical thresholds were measured in the ipsilateral and
contralateral hind paws using the up–down von Frey method.8
Ratswere initially habituated to the testing apparatus (290 [length]
3 170 [width] 3 240 mm [height]) over one session lasting 60
minutes. Rats from cohort 1 failed to show reduced activity in the
boxes over the course of this first habituation, and during
subsequent attempts (once a week over 11 weeks), this cohort
continued to move in response to the presence of the tester, and
so, von Frey testing could not be completed. Cohort 1 rats were
previously trained in a manually run bowl digging task with a lot of
handler interaction, and this may have interfered with the
habituation process. Rats from cohort 2 habituated after one
session and proceeded to von Frey testing. Testing was
performed on weeks 21(day-4), 1(day 4), 6 (day 46), 10 (day
75) postsurgery (Figure 1). Rats were placed into the test
apparatus and left for 30 to 60 minutes. von Frey hairs were
applied perpendicularly to the foot in the area of innervation by the
saphenous nerve (lateral edge of the plantar surface). Von Frey
(vF) withdrawal responses were determined from a stimulus:
response relationship generated using a modified up–down
method8 starting with an 8 g vF force and using 2 g, 4 g, 6 g, 8 g,
10 g, 15 g, and 26 g forces as needed. If a hind paw withdrawal
response was seen in response to 8 g, a lower vF stimulus was
used, and if no withdrawal response occurred, a higher stimulus
force was used until a response was seen. If no withdrawal
response was seen in response to 8 g, a higher vF stimulus
followed until a response was seen, at which point the force
applied was reversed. This reversal process between consistent
withdrawal and nonwithdrawal until 5 reversals had been
completed. From this, mechanical thresholds were determined
using the Dixon’s equation as described in Refs. 8,14.
2.4. Measurement of affective state–related behaviours
To quantify reward deficits linked to depression-like phenotypes,
we used our novel RLA.44 This assaywas developed to quantify in
animals’ deficits in reward-related cognition based on the
hypothesis that the loss of pleasure in previously rewarding
activities, which is a hallmark of MDD Diagnostic Statistical
Manual version V (DSM-V), is related to these deficits. Unlike
behavioural despair models, which are now believed to be limited
to a predictive model of antidepressant efficacy,9,57 our reward-
learning assay has been shown to be sensitive to phenotypic
changes associated with different risk factors for MDD including
early life adversity51 and treatment with prodepressant drugs.53
We also tested animals in the ABT50 to determine whether
acute antinociception would modify affective biases consistent
with a treatment-induced change in the affective state. The ABT
has undergone extensive validation using pharmacological and
psychosocial manipulations of the affective state.24,25,43,50 We
have been able to establish that the task can detect both positive
and negative changes in the affective state through quantification
of the arising affective bias. The ABT, unlike the RLA, uses a
within-subject design and a fixed reward value and so is not a
measure of reward learning per se but quantifies acute affective
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state-induced changes in a specific rewardmemory. Biases arise
when the animal experiences a positive or negative affective state
at the time of learning, and this generates either a shift towards or
away from the treatment-paired reward-association during a
subsequent preference test. In a recent study, we have also been
able to demonstrate that the assay is highly sensitive to individual
differences in an animal’s positive affective experience.24
2.5. Training for the reward-learning assay and affective
bias test
All training and testing was performed in a 40 cm2 clear Perspex
arena in which 2 glazed pottery bowls (10 cm in diameter) were
placed against 1 wall. Training and testing were performed as
described previously in Refs. 25,50,53. In brief, rats were first
trained to dig to obtain a food pellet reward (40-mg precision
pellets, TestDiet, Sandown Scientific, United Kingdom) with the
amount of digging substrate (sawdust only during training)
increased to a final depth of;2 cm. Once trained, rats could be
tested in either a RLA or an ABT using the same basic protocol.
A major advantage of the bowl digging set-up is that the same
motor effort is required for either a correct or incorrect choice
and recordingmeasures of associative learning (trials to criteria),
motivation, and motor function (latency to dig) during the
discrimination learning sessions provide additional control data
for any nonspecific effects. The standard testing protocol was
performed over 5 days and used a within-subject design. During
each discrimination learning session, the rat was presented with
2 digging substrates in discrete trials: one rewarded (CS1, A or
B) and one nonrewarded (CS-, C). A crushed-up food pellet was
added to the unrewarded substrate to reduce olfactory cues.
Rats were allowed to explore both bowls and make a choice of
which to dig in. As soon as the rat chose a bowl to dig in, that is,
nose or paw(s) went below the surface of the substrate, the
other was removed. For each trial, bowls were positioned in a
pseudo-random order, left or right to prevent spatial learning.
The session was complete when either the rat achieved criterion
(6 consecutive correct trials) or completed 20 trials without
achieving criterion. No digging within 20 seconds was counted
as an omission and trials to criterion, as well as the latency to dig
Figure 1.Overview of themethods for the RLA and ABT (panel A), SNC task (panel B), and a timeline of the interventions for cohort 1 and 2 (panel c). The schematic
included for the RLA and ABT illustrate the substrate, reward, and treatments for an example rat. Substrates, day of associative learning, and treatment were all
counter-balanced with different rats receiving different substrate-reward pairings under each condition and with the order of treatments counter-balanced. ABT,
affective bias test; RLA, reward learning assay; SNC, successive negative contrast.
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in each trial, were recorded to determine any nonspecific effects
of treatment. On the fifth day, the 2 previously rewarded
substrates (CS1, A and B) were presented together for the first
time, and preference was determined over 30 trials. Positions of
the bowls were pseudo-random, and trials were randomly
reinforced with a single food pellet, such that the probability of
reward was 1 in 3 for each substrate. For all studies the
substrates, order of presentation and treatments (where
appropriate) were fully counter-balanced to remove any
experimental bias. Substrates used for these experiments were
as follows: aspen chip bedding, cypress bedding, woodchips,
hygiene cloth, exfoliating gloves, small beads, wool, and mouse
bedding.
2.5.1. Reward-learning assay
To test if rats would develop a reward-induced positive bias,
individual substrates (CS1, A or B, randomised to high or low
reward) were paired with either one (low) or 2 (high) food
pellets during the discrimination learning sessions (days 1–4,
Fig. 1). Rats were then presented with both the high and the
low value reward-paired substrates together on the final day,
and their choices recorded over 30 trials. During the
preference test, all trials were rewarded with a single pellet
reward randomly presented in either substrate A or B. A
reward-induced positive bias was observed when rats made
more choices for the substrate previously associated with the
higher value reward.
2.5.2. Affective bias test
In this version of the assay, the absolute value of the reward is
the same for all the discrimination learning sessions, a single
reward pellet. However, one of the substrate-reward associa-
tions is learnt after a control manipulation whereas the other was
learnt after treatment with an analgesic on a separate day
(Fig. 1). (Rats were initially tested using morphine, venlafaxine,
amitriptyline, or vehicle [saline]. However, the venlafaxine
positive control failed to elicit a positive bias in the sham group
possibly due to stress associated with intraperitoneal dosing
which we have found can induce a negative bias in the assay52
[data not shown]). For the gabapentin experiment and to
facilitate oral dosing, before the experiment, rats were trained
to drink strawberry milkshake from a syringe for 1 week. This
then enabled us to avoid the stress associated with oral gavage
or intraperitoneal administration by administering the treatment
in this palatable form. The gabapentin was dissolved in
milkshake at a 1 mL/kg dose volume, and rats would
immediately drink all the milkshake from the syringe, when it
was presented through the cage bars, 1 hour before the learning
session. In this study, both sham and PSNI rats were treated
with either gabapentin (50 mg/kg, oral in strawberry milkshake,
1 mL/kg dose volume, 400 mg capsules, Arrow Generics) or
vehicle (strawberry milkshake, 1 mL/kg dose volume), counter-
balanced over the 4 pairing sessions (drug treatment on day 1
and 3 or 2 and 4) with the same treatment paired with either
substrate A or B. Rats did not receive any treatments before the
choice test. During the choice test, rats were presented with
substrates A and B together for the first time and their choices
recorded over 30 trials. Based on our previous validation of this
assay, a positive bias during the choice test was interpreted as
rats being in a more positive affective state during learning of the
substrate-reward association relative to that during control
conditions.50 The dose used has been shown previously to
reducemechanical and cold allodynia in PSNI59 and when given
orally in the L5/L6 spinal nerve ligation model at this dose and
time-point.22
2.6. The sucrose preference test
The SPT was adapted from the original protocol61 and has been
previously described in Ref. 53. Rats were first habituated to the 2
drinking solutions, water and 1% sucrose, before testing. Starting
72 hours before the test, 1% sucrose replaced normal drinking
water in the home cage for 48 hours, with the aim to prevent
neophagia during the test. This was then replaced by normal
drinking water for 24 hours. Before testing, rats were water
restricted for 4 hours before being housed individually in new
cages and given the choice of 2 bottles: one containing normal
drinkingwater and the other 1% sucrose. The side of the sucrose/
water was counterbalanced across cages, and the total test time
was 1 hour with bottles weighed pretesting and posttesting.
2.7. Successive negative contrast
Training and testingwere performed as described previously.36,42
In brief, all training and testing used 5-hole operant boxes (Med
Associates, Sandown Scientific, United Kingdom) controlled by
K-Limbic software. Only the middle aperture was used for
responding, with reward pellets dispensed into amagazine on the
opposite wall of the chamber. Ratswere trained to initiate a trial by
a nose-poke in the magazine. After initial continuous reinforce-
ment training where the magazine light is illuminated with each
reward delivery, the food reward and magazine light become
associated. In subsequent stages, the light in the magazine alone
is illuminated, and rats learn they need to nose poke to initiate a
trial. After a fixed intertrial interval (ITI), the stimulus light would
come on in the central aperture, and the rats had to nose-poke
this aperture within a limited hold (LH) period. Correct responses
were rewarded with 4 food pellets (40 mg precision pellets,
TestDiet, Sandown Scientific, United Kingdom) delivered to the
magazine. Throughout training, both stimulus and LH duration
were decreased, whereas the ITI was increased, from a starting
duration of 2 seconds. The final stage had a stimulus duration of
10 seconds, LH of 10 seconds, and ITI of 20 seconds. Each
session consisted of 50 trials. Once rats had met criteria for 2
consecutive trials, at this final stage, they were considered
trained. To establish baseline, presurgery performance, rats were
then tested for 10 sessions, including 3 devalue, on weeks
postsurgery-3 (day-17) and 2 (day-13 and day-10). Devalue
sessions were always run as single session with a least 2 days
between the test. For each devalue session, a correct response
was rewarded with only a single pellet rather than the training and
baseline level of 4 pellets. We have previously shown that this
reduction in reward outcome results in a negative contrast effect
consistent with the criteria previously described by Crespi.11
Based on previous studies, reducing the expected value of the
reward increases correct and collection latency and omissions
and reduces premature responses.11,36 As our primary interest
was to compare the response of rats in chronic pain to controls
during baseline and devalue sessions, we did not include control
groups which only ever received the lower value reward.
After baseline testing, rats were split into 2 counter-balanced
groups and underwent sham or PSNI surgery as described
above. After 1-week recovery, rats were returned to behavioural
testing using the final training stage. Rats were tested over 4
sessions to re-establish a stable baseline. They were then tested
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for 4 sessions under baseline conditions to determine if there
were any effects of nerve injury before progressing to testing rats
during both baseline and devalue sessions. Rats were tested in 6
devalue sessions on days 7 to 45 postsurgery.
2.8. Statistical analysis
2.8.1. Experiment design and methods to reduce bias
The sample size used was based on a power calculation using
GPower3.1.9.2 andpreviousdata from the laboratory using thebowl
digging tasks and operant SNC.50 The experimenter was blind to
drug treatment, but not the surgery group, for all the behavioural
testing except the von Frey studies in which rats were pseudor-
andomly placed into the test boxes by a different researcher to the
oneundertaking the test. All drug dosing and factors such asdigging
substrate and order of the pairing sessions for the RLA and ABT
were counter-balanced to reduce experimental bias.
All graphs were created in GraphPad Prism version 5.03, and
thiswas used for t test analysis in the tasks specified below. SPSS
Statistics 23 IBM was used to conduct repeated measure
analysis of variance (ANOVA) and post-hoc analysis when
appropriate. A Huynh–Feldt correction was used to correct for
violation of sphericity. Where significant main effects or interac-
tions were observed (P , 0.05), effects were further analysed
using post-hoc tests with appropriate correction for multiple
comparisons, for example, Bonferroni for within-subject com-
parisons and Sidak for between subject.
Mechanical thresholds were determined using Dixon’s equa-
tion: mechanical  threshold 5 ð10½xf1 kdÞ=10000.8,14 In
which xf is the last force used, k is a constant specific to the
response pattern (defined in Refs. 8,14), and d is the average
difference between each force used. The results for the normality
test (Shapiro–Wilk test) for the specific groups and time-points
found most of the data were normally distributed (only 3 of the 16
values were significant), and Levene’s test satisfied the assump-
tions for RM ANOVA. Therefore, differences between sham and
PSNI and presurgery baselines were analysed using a mixed
model ANOVA with treatment GROUP (between-subject factor)
and DAY (within-subject factor). Data from the ipsilateral and
contralateral paws were analysed using separate ANOVAs.
Data from theRLA andABT study are presented as percentage
choice bias. This was calculated as {[(number of choices of
gabapentin or 2 pellet-paired substrate)/(number of choices of
vehicle or 1 pellet-paired substrate)] 3 100}250. This gave a
percentage preference in which a positive value denotes a bias
towards the gabapentin/2-pellet paired substrate, and a negative
value indicates a preference towards the vehicle/1-pellet paired
substrate. Statistical analysis was a one-tailed, unpaired t test for
comparison between sham and PSNI rats as well as individual 1
sample t-tests against a theoretical mean of 0% choice bias.
Percentage preference for the sucrose solution in the SPT was
determined as [weight of sucrose solution consumed/(weight of
sucrose solution consumed 1 weight of water solution con-
sumed)] 3 100. Total fluid consumed is represented in grams.
Comparison between sham and PSNI rats was conducted by a
2-tailed t test in GraphPad Prism.
For the SNC task, variables recorded were as follows: number
correct, omissions (not responding within the LH), and premature
(response before the light stimulus) alongside both correct and
collection latencies (time to respond to stimulus and time to collect
reward respectively). In contrastwith the5-choice serial reaction time
task, there were no incorrect responses recorded in this task as only
the central aperture was in use. Data were analysed using a mixed
model ANOVA with treatment GROUP (between-subject factor),
TIME (within-subject factor), and SESSION (within-subject factor).
3. Results
3.1. Partial saphenous nerve injury–induced
mechanical allodynia
Consistent with previous studies, rats receiving nerve injury developed
allodynia with reducedmechanical threshold in the ipsilateral (Fig. 2A)
but not contralateral paw (Fig. 2B). There were no significant main
effects on contralateral thresholds, but GROUP, DAY, AND GROUP
3 DAY were all significant on the ipsilateral paw (GROUP F(1,21) 5
13.285 P5 0.002, DAY (F(2.814, 59.091)5 13.194 P, 0.001), and
GROUP*DAY interaction (F(2.814,59.091)53.910P50.02Fig. 2A).
Postsurgery ipsilateral measurements, made on days 46 and 75,
showed reduced threshold for the PSNI rats compared with sham
(day 46 P 5 0.001 day 75 P 5 0.006), and all PSNI ipsilateral
postsurgery measurements were lower than presurgery values (day 4
P5 0.004 day 46 P, 0.0001, and day 75 P, 0.0001).
3.2. Impaired reward learning after partial saphenous
nerve injury
Before surgery, both treatment groups developed a reward-induced
positive bias in the RLA. When rats were retested 14 days
postsurgery, using new substrate-reward associations, compared
with the null hypothesis of 0%, the sham group developed a reward-
induced positive bias (1 sample t1552.936, P5 0.01) but the PSNI
animals did not (Fig. 3A). A pairwise comparison between sham and
PSNI also found that the reward-inducedpositive biaswas attenuated
in PSNI animals (t test, t30 5 3.144, P 5 0.002). There were no
differences between groups during the discrimination learning
sessions in either trials to criteria or latencies postsurgery (Figs. 3B,
C, respectively). These control measures suggest rats were not
impaired in their ability to learn the associations during the initial pairing
sessions and had no overt motor impairments. The effects observed
were therefore specific to impairments during retrieval in the choice
test and suggest an impaired ability to use the prior information about
reward value to guide decision-making.
3.3. Gabapentin induces a positive affective bias in partial
saphenous nerve injury rats alone
Treatmentwithgabapentin (50mg/kg, oral) inducedapositive bias in
thePSNI treatedgroupcomparedwith controls (1-tailed t2852.011,
P5 0.027, Fig. 4A) and a tendency to positive biaswhen compared
against the theoreticalmean of 0%bias (1 sample t test, t135 1.836,
P 5 0.089). Sham rats did not show any bias and neither group
showed any effect of treatment on trials to criterion (total number of
trials taken to achieve criteria of 6 consecutive correct trials) or the
latency to dig (Figs. 4B,C), suggesting therewas no effect of drug on
learning and memory or general motor function.
3.4. No changes in reward sensitivity in the sucrose
preference test after partial saphenous nerve injury
Both groups developed a sucrose preference with sham (1
sample t155 8.864 P, 0.0001 n5 16) and PSNI (1 sample t155
3.948 P 5 0.0013 n 5 16) treated rats showing a preference for
1% sucrose vswater when comparedwith a hypothetical mean of
0% bias (Fig. 5A). There was no difference between groups in
percentage preference (Fig. 5A) or total fluid consumption
(Fig. 5B).
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3.5. No evidence of changes in motivation for reward or the
successive negative contrast effect after partial saphenous
nerve injury
Consistent with previous studies, the rats trained in the SNC task
expressed a devalue effect when the reward outcomes were
unexpectedly reduced from4 to 1 pellet.36,42 All rats completed the
maximum number of trials in all baseline and devalue sessions.
During each devalue session, there was an increase in both time to
respond to the cue (correct latency, SESSION (F(1,19)5 60.907 P
, 0.0001, Figure 6A) and time to collect the reward after delivery
(collection latencies, SESSION F(1,19) 5 14.115 P 5 0.001, Fig.
6B). Rats also reduced their premature responses (SESSION
F(1,19)5 30.766 P, 0.0001, Fig. 6C) and increased the number
of trials they omitted (SESSION F(1,19) 5 22.258 P , 0.0001,
Fig. 6D) in the devalue sessions relative to baseline, although post-
hoc data did not show a consistent difference unlike between
sessions latency data. Postsurgery, both sham and PSNI
performed the task at a similar level to their presurgery baseline,
Figure 2. PSNI-inducedmechanical allodynia in the ipsilateral but not contralateral paw. (A) Ipsilateral, (B) contralateral data shown asmean6 SEM, n5 11 sham
n5 12 PSNI. Data were analysed using a repeatedmeasures ANOVA. **P, 0.01 between-group difference ## P, 0.01, ### P, 0.001 within-group difference,
ns nonsignificant within-group difference. 1 shamwas excluded from analysis for being consistently 2 standard deviations away from the mean. ANOVA, analysis
of variance; PSNI, partial saphenous nerve injury.
Figure 3. Impairments in reward learning in PSNI rats, postsurgery. (A) Postsurgery sham rats preferred the 2-pellet paired substrate (1 sample against null
hypothesis of 0% t15 5 2.936, P5 0.0102 n5 16), but PSNI showed no bias. There was a significant difference between groups (1-tailed t test t30 5 3.144, P5
0.002 n 5 16 per group). There was no effect of PSNI, when compared with sham, on trials to criterion (B) or latency to dig (C) during discrimination learning
sessions. *P, 0.05 compared with a null hypothesis of 0% bias, ##P, 0.01 PSNI compared with sham rats. n5 16 for both sham and PSNI. Data are expressed
as mean 6 SEM. PSNI, partial saphenous nerve injury.
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with no effect of GROUP or GROUP 3 SESSION during either
baseline or devalue sessions. There were no changes in correct or
collection latencies over the period of testing, including after
surgery, because there was no significant effect of TIME or
interactions with TIME. However, in both sham and PSNI groups,
there was a decrease in premature responding over the period of
testing (TIME F(3.987,75.758) 5 3.950, P 5 0.011), which was
greater for the baseline sessions (SESSION 3 TIME F(5,95) 5
2.810 P5 0.019). Omissions generally reduced over testing (TIME
F(4.659,88.512) 5 2.523, P 5 0.038) and also reduced more for
devalue sessions (SESSION3 TIME F(5,95) 5 2.539 P 5 0.033).
Overall, there was also no evidence that chronic pain changes
motivation to respond for reward in this operant task or the SNC
effect.
4. Discussion
Consistent with previous studies, we observed that rats receiving
a PSNI developed allodynia consistent with a chronic pain
phenotype.27,59 The allodynia developed over time and was
present during the behavioural studies. Results from the different
measures of reward processing revealed dissociable effects with
rats from the nerve injury group exhibiting an attenuated reward-
induced positive bias. These effects were not related to changes
in reward sensitivity in the SPT or changes in reward motivation.
These findings concur with recent data obtained from putative
models of depression suggesting that rats experiencing chronic
pain exhibit similar impairments in reward processing to rats
exposed to known depression risk factors of early life stress,51
chronic treatment with a prodepressant drug (retinoic acid) or a
known, prodepressant immune-based treatment, interferon
alpha.53 In the ABT, rats experiencing chronic pain developed a
positive affective bias after treatment with the atypical analgesic,
gabapentin, relative to the sham controls. This suggests that
gabapentin-induced antinociception induces a relatively more
positive state possibly arising from remediation of a negative
affective state resulting from chronic pain, but gabapentin itself
does not modify affective state. These data provide evidence for a
deficit in reward processing which is consistent with a
depression-like phenotype arising from chronic pain. Chronic
pain animals remain sensitive to reward-related affective biases
as seen in the depression models51 suggesting different un-
derlyingmechanisms to those detected in the Pavlovian RLA. The
following discussion considers these different measures of
reward processing in the context of both chronic pain and
depression-related research and possible implications for un-
derstanding their comorbidity.
In this study, we used the PSNI model, in which the injury is to a
purely sensory nerve, to reduce potential motor effects. There
was no evidence of PSNI-induced locomotor deficits in either the
bowl digging or SNC tasks, because no differences in response
latencies were observed between groups, despite the presence
of allodynia. We did observe a small decrease in threshold in the
sham group shortly after surgery, but the difference between
groups was clear from day 46 and for the remainder of the period
of testing consistent with previous findings for this model.27,59
Alongside, using a model which lacks ventroflexion of the toes,
we also used behavioural tasks where any differences in motor
function were controlled for within the experiment design. In
addition to controlling for motor effects, we did not see any
evidence of cognitive impairments in either bowl digging tasks.
During the learning phase of these tasks, no differences were
Figure 4. Gabapentin induce a positive bias in PSNI rats relative to shams. (A) PSNI rats showed a positive bias towards the substrate learnt after gabapentin
treatment compared with controls (1-tailed t test t28 5 2.011 P 5 0.027) and a tendency to a positive bias compared against the null hypothesis of 0% bias (1
sample t test, t135 1.836, P5 0.089). There was no effect of gabapentin treatment in either group in terms of associative learning (trials to criterion and number of
trials taken to achieve 6 consecutive correct trials) (B) or latency to dig (C) in discrimination learning sessions. n5 16 for both sham and PSNI. Data are expressed
as mean 6 SEM. PSNI, partial saphenous nerve injury.
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observed between groups. Rats had similar trials to criterion
during learning in the RLA and ABT. This is consistent with the
lack of learning deficit seen in other chronic pain models and
reward-motivated learning tasks10,41 although it should be noted
that cognitive deficits in spontaneous tasks such as novel
objective recognition have been observed.30,31,39,55,62
Figure 5. No deficits in reward sensitivity in PSNI rats in the SPT. (A) There was no difference between sham and PSNI in percentage sucrose consumed over 1
hour (1-tailed t test t305 0.9501P5 0.1748 n5 16 in each group). Both shamandPSNI groups had a significant preference from the null hypothesis of 50%: sham
(one sample t155 8.864P, 0.0001 n5 16), PSNI (1 sample t155 3.948P5 0.0013 n5 16). (B) PSNI did not induce any significant changes in fluid consumption.
n 5 16 both sham and PSNI. Data are expressed as mean 6 SEM. PSNI, partial saphenous nerve injury.
Figure 6.Neither motivation to respond for reward nor the SNC effect was affected by PSNI. There were no differences between groups during baseline testing for
any of themeasures recorded.When the number of food pellets for a correct response (nose-poke in the central aperture when lights were on) was reduced from 4
to 1 pellet, both sham and PSNI rats showed a similar devalue effect. Similar increases in correct latency (A) (time to nose-poke after light on in the aperture) and
collection latency (B) (time to collect reward after it was dispensed) were seen in both sham and PSNI groups. There was a significant main effect and decrease in
premature responding (responses made during the ITI) (C) and an increase in omissions (failing to respond during the limited hold) (D), but again, there were no
differences between shamand PSNI rats. Data shown asmean6SEM, shamn5 10, PSNI n5 12. Datawere analysed by repeatedmeasures ANOVA. #P, 0.05
##P, 0.01 ###P, 0.001 significant difference between preceding baseline and devalue session, taking sham and PSNI data together. 1 shamwas excluded for
consistently being 2 standard deviations away from the mean in pain testing, another for operant box error. BL: baseline session in which a correct response was
rewarded with 4 pellets. DV: devalue session in which the number of pellets for a correct response was reduced to 1 pellet. ANOVA, analysis of variance; ITI,
intertrial interval; PSNI, partial saphenous nerve injury; SNC, successive negative contrast.
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Deficits in reward processing in MDD in patients use methods
which are not readily translated to animal studies.44 Questionnaire
measures of anhedonia in patients are complicated by their
subjective nature, and it is not always obvious whether the deficits
relate to the ability to experience pleasure, the ability to anticipate
reward or reward-related cognition48 Recently, it has been
suggested that reward deficits in MDD may relate more to reward-
related memory rather than inherent reward sensitivity.48,56 There is
no consensus on the presence of deficits in reward sensitivity in
chronicpainmodels. Somestudies report reduced reward sensitivity
in theSPT,2,12,16,35,54,60,62 and others did not.17,46,58Othermethods
to assess reward sensitivity such as intracranial self-stimulation15
and changes in facial expressions in response to reward41 also
found no deficits in chronic pain models. Here, similar to some
putative models of MDD,51,53 PSNI displayed no changes in reward
sensitivity in the SPT but failed to develop a reward-induced positive
bias in a novel bowl-digging task. We only tested a 1 hour, 1% SPT
based on the original model designed to test for stress-induced
reward deficits61 and to use the same methods as previously
reported for our depressionmodel;51 however, other protocols have
been used and may give different results. A separate cohort of rats
also showed no changes in motivation for reward in the SNC task
under normal conditions or after reward devalue. Taken together,
these data suggest that the PNSI pain model exhibits specific
impairments in reward learning similar to effects seen in rodent
models of depression.53 These deficits are independent of any
change in reward sensitivity and do not seem to be related to
motivation as measured in the SNC task.
The ABT has been extensively investigated using antidepressant
and prodepressant manipulations.25,43,50 The finding that PSNI rats
exhibit a significantly more positive bias towards gabapentin
suggests the rewarding aspects of antinociception are driving a
positive bias. It would be interesting to test if antidepressant drugs,
also used to treat chronic pain, induce similar positive biases,
although we know from previous studies that similar treatments
induce positive biases in control rats.50 The findings with gabapentin
are different because it did not have any apparent effects in sham
rats suggesting a specific interaction with the pain state. Although
both the ABT and RLA investigate reward-related behaviours, the
tasks are designed to look at different aspects of reward-related
cognition. In the RLA, animals learn to associate cue-reward
associations under the same core affective state, and biases are
induced by the recall of the reward value predicted by the cue. In the
ABT, the reward value is fixed with the arising biases correlated with
the short-term affective state change induced alongside the
treatment-paired cue. Previous studies in depression models
suggest that animals with impaired reward learning are still able to
develop affective state–inducedbiases, andalthoughpositive biases
remain unaffected, negative biases are potentiated.51 Although
insights into the neuropsychological mechanisms which underlie
these different behaviours are limited, the evidence to date suggests
the reward-learning and reward-related affective biases are not
mediated by the same neuropsychological mechanisms. Previous
studies using conditioned place preference, to assess the rewarding
effect of pain relief with gabapentin, found similar results in which
chronic neuropathic pain rats, but not sham, preferred the
gabapentin-paired chamber.4 The dose used in the current study
has previously been shown to reduce allodynia in the PSNI pain
model.59Although this is only a single study in theABTandhassome
limitations to the findings, it may be that this task offers a novel
approach to assessing new analgesics with a focus on the affective
component of pain especially in the context of neuropsychological
deficits.
The SNC task investigated how rats respond to an un-
expected change in reward outcome. The contrast effect results
in animals showing a lower level of motivation to respond than
the level of control animals that have only ever experienced the
lower value reward.11,36 In this study, similar responses to the
devalue sessions were observed in both the PSNI group and
sham controls. All rats exhibited similar increases in correct and
collection latencies as well as main effects of the session on
omissions and premature responses when the reward de-
creased from 4 to 1 reward pellet(s). There was also no
difference observed between groups during the baseline
sessions. Some studies have suggested that negative affective
states may potentiate the devalue effect;18 however, the results,
here, do not suggest the PSNI-induced pain modifies this
behaviour. To the best of our knowledge, this is the first study to
investigate motivation for reward in an SNC task in a chronic
pain state, although other studies have looked at motivational
behaviour in progressive ratio tasks.22,41,45 Current findings are
inconclusive with one study reporting a reduction in breakpoint,
indicating reduced motivation for reward,45 whereas others
found no effects.22,41 In our study, motivation for immediate
reward is not impaired in chronic pain and further supports our
proposal that deficits in reward learning may be more relevant to
reward-related impairments which can present in chronic pain
patients.
Chronic pain is commonly associated with symptoms of
MDD.3 The results presented here show that the relatively mild
PSNI model exhibits similar impairments in reward learning to
those seen, using the same assay, in putative models of
depression.51 These impairments in reward-induced positive
bias are specific and dissociable from other aspects of reward
processing with rats showing no impairment in either reward
sensitivity or motivation. Alleviating the pain in this model with
gabapentin, resulted in a more positive affective bias relative to
the vehicle-treated state, although with only a trend level effect
observed. These findings concur with other pharmacological and
phenotypic studies into the neuropsychological processes which
may contribute toMDD.51,53 Our laboratory has shown that acute
prodepressant treatments induce negative affective biases in the
ABT, and, when experienced chronically, also induce impair-
ments in reward-related cognition.51,53 This suggests that
chronic painmay affect mood through similar neuropsychological
mechanisms, that is, pain generates a negative affective state
which, when experienced chronically, leads to deficits in reward
learning. Newmethodswhich can be used to assess the potential
efficacy of novel analgesics and that reduce the reliance on
changes in sensory processing are needed.37 By quantifying
changes in affective state either acutely using the ABT or
chronically through measurements of reward-related cognition,
it may be possible to develop new analgesics which are also
efficacious on the emotional component of chronic pain. One
limitation of the current studies was the use of only a single sex.
Although we have shown that similar affective biases are
observed in male and female rats,25 it will be important that
studies with a specific focus on understanding if there are sex
differences in these effects are undertaken.
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